July 2020 FDA Recall Auryxia by Keryx Biopharmaceuticals, Inc.
D-1389-2020 - cGMP deviations

This Class II drug recall was voluntarily initiated by Keryx Biopharmaceuticals, Inc. on July 10, 2020 for the product Auryxia. The FDA reported the reason for recall as cgmp deviations. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-1389-2020

Reason for Recall
cGMP deviations: Lots recalled were not manufactured in conformance with the FDA-approved manufacturing process for Auryxia.
Initiated
07-10-2020
Reported
07-22-2020
Quantity
59,820 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Keryx Biopharmaceuticals, Inc.
Nationwide in the U.S.
Auryxia (ferric citrate) tablets 210 mg, Rx Only, 200 tablets per bottle, Manufactured for and distributed by: Keryx Biopharmaceuticals, Inc., 245 First Street Suite 1400, Cambridge, MA 02142, NDC: 59922-631-01.

Batch or Lot Expiration Information

Lot# s: AK6003C, Exp. 10/31/2020; AK6004B, Exp. 11/30/2020; CBMKF, CBMKH, Exp. 08/31/2020; CCKSM, Exp. 09/30/2020; CBWKN, Exp. 11/30/2020; CCSTZ, CCWZB, Exp. 05/31/2021; CCYSF, CCYSG, CCWZC, Exp. 06/30/2021; CDCTB, CDCSZ, Exp. 07/31/2021.

Affected Packages Involved in this Recall